Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Adjustment of insulin Degludec to Reduce post-Exercise (nocturnal) hypoglycaeMia in people with diabetes – the ADREM study

Trial Profile

Adjustment of insulin Degludec to Reduce post-Exercise (nocturnal) hypoglycaeMia in people with diabetes – the ADREM study

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 09 Mar 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Insulin degludec (Primary)
  • Indications Type 1 diabetes mellitus
  • Focus Therapeutic Use
  • Acronyms ADREM

Most Recent Events

  • 07 Mar 2023 Results published in the Diabetologia
  • 23 Sep 2022 Primary endpoint (Time spent in hypoglycaemic range (i.e. glucose 3.8 mmol/l) during the night (00:00 to 05:59h) following the exercise day measured by continuous glucose monitoring.) has been met, as per results presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
  • 23 Sep 2022 Results assessing three degludec dosing regimens after a 45-minute exercise test on a bicycle ergometer, followed by blinded continuous glucosemonitoring for 6 days, presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top